Science
Publications
European Urology 2025
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry
Karpinski M.J. et al. Emmett L.
Eur Urol. 2025 Read the Article
European Urology 2025
European Initiative for Standardized Reporting in Prostate Cancer endorses PROMISE;
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
Herrmann K. et. al. Bjartell A.
Eur Urol. 2025 Sep 12:S0302-2838(25)00482-8. Read the Article
European Urology 2025
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study
Karpinski M.J. et al. Fendler W.P.
Eur Urol. 2025 Nov;88(5):484-495. Read the Article
Current Opinion Urology 2025
Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrence
Karpinski M.J. et al. Fendler W.P.
Curr Opin Urol. 2025 Sep 1;35(5):506-509. Read the Article
European Urology 2024
Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
Fendler W.P. et. al. Hadaschik B.A.
Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. Read the Article
Lancet Oncology 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.
Karpinski M.J. et al. Fendler W.P.
Lancet Oncol. 2024 Jul 29:S1470-2045(24)00326-7. Read the Article
European Urology 2023
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R. et. al. Eiber M.
Eur Urol. 2023 May;83(5):405-412. Read the Article
EJNMMI 2023
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Fendler W.P. et. al. Herrmann K.
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1466-1486. Read the Article
JNM 2018
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Eiber M. et. al. Fendler W.P.
J Nucl Med. 2018 Mar;59(3):469-478. Read the Article
Oral Presentations
EANM 2025
Impact of Radiotherapy on Overall Survival in Prostate Cancer Patients with Biochemical Recurrence Staged by PROMISE Criteria Using PSMA-PET
Civan C. et. al. Guberina N.
SNMMI 2025
Three-tier risk stratification of prostate cancer by PSMA-PET PROMISE (PPP2): Results from an international multi-centre registry study
Karpinski M.J. et. al. Hoberück S.
Journal of Nuclear Medicine June 2025, 66 (supplement 1) 251292; Read the Abstract
AUA 2025
Prostate cancer risk groups by PSMA-PET PROMISE (PPP): Results from an international multi-center registry study
Kesch C. et. al. Hadaschik B. A.
EAU 2025
Prostate cancer risk groups by PSMA-PET PROMISE (PPP): Results from an international multi-center registry study
Kesch C. et. al. Hadaschik B. A.
EANM 2024
PSMA-PET and PROMISE re-define stage and risk in prostate cancer patients
Karpinski M.J. et. al. Fendler W.P.
ASCO 2024
Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer.
Fendler W.P. et. al. Hadaschik B. A.
ASCO24 Abstract 5016 and Journal of Clinical Oncology, Volume 42, Number 16_suppl. Read the Abstract